Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Beam Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Beam Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$355.78M. For fiscal 2025 it was -$361.40M. The highest annual figure on record is -$71.65M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$361.40M | – |
| FY2024 | Dec 31, 2024 | -$393.64M | – |
| FY2023 | Dec 31, 2023 | -$156.47M | – |
| FY2022 | Dec 31, 2022 | -$324.33M | – |
| FY2021 | Dec 31, 2021 | -$385.01M | – |
| FY2020 | Dec 31, 2020 | -$128.03M | – |
| FY2019 | Dec 31, 2019 | -$71.65M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$121.14M | – |
| Q1 FY2026 | Mar 31, 2026 | -$101.61M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.78M | – |
| Q3 FY2025 | Sep 30, 2025 | -$121.25M | – |
| Q2 FY2025 | Jun 30, 2025 | -$114.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$113.76M | – |
| Q4 FY2024 | Dec 31, 2024 | -$94.59M | -168.4% |
| Q3 FY2024 | Sep 30, 2024 | -$101.03M | – |
| Q2 FY2024 | Jun 30, 2024 | -$99.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$98.70M | – |
| Q4 FY2023 | Dec 31, 2023 | $138.22M | – |
| Q3 FY2023 | Sep 30, 2023 | -$103.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$97.33M | – |
| Q1 FY2023 | Mar 31, 2023 | -$94.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$85.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$87.83M | – |
| Q2 FY2022 | Jun 30, 2022 | -$78.55M | – |
| Q1 FY2022 | Mar 31, 2022 | -$72.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$60.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$67.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$57.31M | – |
| Q1 FY2021 | Mar 31, 2021 | -$198.98M | – |
| Q4 FY2020 | Dec 31, 2020 | -$39.53M | – |
| Q3 FY2020 | Sep 30, 2020 | -$36.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.14M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.26M | – |
See a number that looks wrong?